stockrowBillionToOne, Inc. (BLLN) vs NeoGenomics, Inc. (NEO)
- BillionToOne, Inc. BLLN 111.96 −1.69%
- NeoGenomics, Inc. NEO 16.55 −3.50%
BillionToOne, Inc. and NeoGenomics, Inc. are both Diagnostics & Research companies. BillionToOne, Inc. is the larger, with a market value of $5.3B against $2.1B — 2.5× the size. NeoGenomics, Inc. has negative trailing earnings, so its P/E is not meaningful; BillionToOne, Inc. trades at 88.7×. BillionToOne, Inc. grew revenue faster over the last twelve months: 76.5% against 11.1%. BillionToOne, Inc. has the higher net margin (11.2% vs −4.10%) and the higher return on invested capital (0.00% vs −2.97%). Across the 18 metrics below, BillionToOne, Inc. leads on 15 and NeoGenomics, Inc. on 3.
Valuation
Profitability
| Metric | BLLN | NEO | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 71.41% | 44.77% | 48.32% |
| Operating margin | 10.23% | (6.27%) | (5.68%) |
| Net margin | 11.23% | (4.10%) | (4.10%) |
| Free cash flow margin | 7.76% | (3.37%) | 0.00% |
| Return on equity | 0.00% | (3.94%) | 0.00% |
| Return on assets | 9.02% | (2.35%) | (6.05%) |
| Return on invested capital | 0.00% | (2.97%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack